Moreover, Siglec-9 has also been reported in myeloid cell-mediated cancer progression via binding to MUC-1 with sialylated T-antigen (MUC-1 ST) in breast cancer and pancreatic ductal adenocarcinoma to modulate tumor-associated macrophage differentiation [92,109]. Here, MUC1 is linked to breast cancer.